All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
In January 2018, Mohamad Bassam Sonbol from the Hematology and Oncology Division of Mayo Clinic, Phoenix, AZ, and colleagues, investigated the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) treatment against low-grade non-Hodgkin lymphoma (NHL), in a phase II study (NCT00711828), published ahead of print in Leukemia & Lymphoma.
Rituximab alone has proved to be a successful first-line treatment against indolent mature B-cell lymphoma (NCT00112931), nevertheless disease progression and relapse, following rituximab, still occur in a patient fraction. The aim of this study was to assess whether a combined drug regiment (R-CyBorD) benefits relapsed or refractory patients, with various types of low-grade NHL. The primary endpoint of the study was objective response rate (ORR on assessment), as defined by either a complete response (CR) or a partial response (PR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), duration of response (DOR) and safety, following administration of R-CyBorD.
The results from this phase II trial suggested that the combined use of rituximab with cyclophosphamide, bortezomib and dexamethasone might be effective in only certain NHL subtypes. In support of this, patients with relapsed or refractory FL had a higher response rate from R-CyBorD treatment (ORR = 88%) than MCL patients (ORR = 25%). Along with the differential effect of R-CyBorD on NHL subtypes, drug toxicity should also be taken into careful consideration. Although manageable, Grade ≥ 3 AEs were observed in a considerable number of patients (67%) and were mainly of a hematologic phenotype. A main limitation of the study, mentioned by the authors, was that the overall sample size was small and because of this, so was the sample size within the NHL subtypes. The authors hope that with further larger randomized trials, R-CyBorD could be a potential treatment option for relapsing patients with FL or LPL/WM.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?